STOCK TITAN
  1. Home
  2. News
  3. EFTR

eFFECTOR Therapeutics Inc - EFTR STOCK NEWS

Welcome to our dedicated news page for eFFECTOR Therapeutics (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on eFFECTOR Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect eFFECTOR Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of eFFECTOR Therapeutics's position in the market.

News
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) will present at the Stifel Virtual Oncology Forum on April 16th, discussing their selective translation regulator inhibitors for cancer treatment. The webcast will be live on their website with a 90-day replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
conferences
-
News
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) announces topline results from the Phase 2 KICKSTART trial for tomivosertib in NSCLC, showing promising PFS results but not meeting statistical significance. The company shifts focus to developing zotatifin for ER+ breast cancer with positive data and plans for upcoming trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.03%
Tags
clinical trial
-
News
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) provided updates on their Phase 2b KICKSTART trial for tomivosertib in NSCLC and zotatifin in ER+ breast cancer. They expect topline data in early April 2024, with positive results potentially leading to Phase 3 trials. The company raised $15.0 million in financing, extending cash runway into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
earnings
News
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14th. The company is a leader in the development of selective translation regulator inhibitors for cancer treatment. The presentation will be available via live webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences
-
News
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) has completed a registered direct offering, selling 1,488,834 shares of its common stock and short-term warrants to purchase an additional 1,488,834 shares. The offering generated approximately $15 million in gross proceeds, with H.C. Wainwright & Co. acting as the exclusive placement agent. The Company plans to utilize the funds for general corporate and working capital purposes, including research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
offering
-
News
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) has announced a definitive agreement for the purchase and sale of 1,488,834 shares of its common stock and warrants to purchase up to the same number of shares at an offering price of $10.075 per share. The warrants will be exercisable immediately upon issuance, with an exercise price of $9.95 per share. The closing of the offering is expected soon, and the funds raised will be used for general corporate purposes and to support the development of its selective translation regulator inhibitors for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.74%
Tags
offering
News
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announces a virtual investor R&D Day on January 24, 2024, to review the development progress of tomivosertib and zotatifin, including recently announced interim data from dose escalation and Phase 2 expansion cohorts of zotatifin in ER+ metastatic breast cancer patients. The company also previews anticipated 2024 milestones and topline results from the Phase 2b KICKSTART clinical trial of tomivosertib combined with pembrolizumab for the treatment of frontline NSCLC in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.84%
Tags
conferences
-
News
eFFECTOR Therapeutics Announces Reverse Stock Split
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced a 1-for-25 reverse stock split of its common stock, effective on January 12, 2024, to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. The reverse split will reduce the number of issued and outstanding shares from approximately 74.9 million to 3.0 million shares, with the total authorized number of shares of common stock being reduced from 1,000,000,000 to 40,000,000 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.84%
Tags
none
-
News
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced positive interim data from a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer. The median progression free survival (mPFS) was 7.4 months in the ZFA expansion cohort, and zotatifin was generally well tolerated as dose escalation continues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
News
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) receives Fast Track designation from the FDA for zotatifin in combination with fulvestrant and abemaciclib as second- or third-line therapy for ER+/HER2- advanced or metastatic breast cancer. The company plans to present data updates and further development plans at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
clinical trial
Stock EFTR logo
eFFECTOR Therapeutics Inc

Nasdaq:EFTR

EFTR Rankings

N/A Ranked by Market Cap
#2937 Ranked by Stock Gains
N/A Ranked by Dividends

EFTR Stock Data

7.67M
3.38M
3.63%
17.57%
9.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About EFTR

effector therapeutics is a biotechnology company located in 11180 roselle street, san diego, ca, united states.